Biodesix Inc (BDSX)vsWaters Corporation (WAT)
BDSX
Biodesix Inc
$17.35
-6.30%
HEALTHCARE · Cap: $161.55M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 3823% more annual revenue ($3.77B vs $96.10M). WAT leads profitability with a 11.9% profit margin vs -33.3%. WAT earns a higher WallStSmart Score of 50/100 (C-).
BDSX
Avoid31
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.0%
Fair Value
$8.70
Current Price
$17.35
$8.65 premium
Margin of Safety
-84.0%
Fair Value
$178.93
Current Price
$365.36
$186.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 42.3% year-over-year
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 19.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -349.9% — below average capital efficiency
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDSX
The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 42.3% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : BDSX
The primary concerns for BDSX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.84 is elevated, increasing financial risk.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
BDSX profiles as a hypergrowth stock while WAT is a growth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.20 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
BDSX generates stronger free cash flow (-10M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 31/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biodesix Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?